Yang Liang, Sun Wan-qing, Wang Li, Wang Xiu-li, Wan Min, Yu Yong-li, Wang Li-ying
Department of Molecular Biology, Norman Bethune Medical College, Jilin University, Changchun, China.
Xi Bao Yu Fen Zi Mian Yi Xue Za Zhi. 2009 Feb;25(2):115-7.
To investigate the potential effect of a self-designed C-type CpG ODN (D-SL01) on coxsackie virus B3 (CVB3) infection.
HeLa cells infected by CVB3 were used as cell a model and BALB/c mice inoculated with CVB3 were used as an animal model for evaluating the anti-viral effect of D-SL01.
The supernatants of D-SL01-treated PBMC protected HeLa cells from CVB3 infection and Vero E6 cells from VSV infection. However, in vivo study showed that D-SL01 reduced the body weight of CVB3-infected mice and aggravated the pathological changes related to myocarditis in mice when they were intraperitonealy injected for 6 days in succession.
When used for the treatment of viral-infected diseases in vivo, CpG ODN may function in a complicated way, which indicates its administration time, route and dosage, should be taken into full consideration.
研究自行设计的C型CpG寡核苷酸（D-SL01）对柯萨奇病毒B3（CVB3）感染的潜在影响。
以CVB3感染的HeLa细胞作为细胞模型，以接种CVB3的BALB/c小鼠作为动物模型，评估D-SL01的抗病毒效果。
经D-SL01处理的外周血单核细胞（PBMC）的上清液可保护HeLa细胞免受CVB3感染，保护Vero E6细胞免受水泡性口炎病毒（VSV）感染。然而，体内研究表明，连续6天腹腔注射D-SL01会使感染CVB3的小鼠体重减轻，并加重小鼠心肌炎相关的病理变化。
当用于体内治疗病毒感染性疾病时，CpG寡核苷酸可能以复杂的方式发挥作用，这表明应充分考虑其给药时间、途径和剂量。
Zotero 插件